{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T16:34:51Z","timestamp":1784219691979,"version":"3.55.0"},"reference-count":31,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:00:00Z","timestamp":1708387200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and Aims<\/jats:title><jats:p>The economic impact of managing patients with hepatitis C virus (HCV) infection remains unknown. This study aimed to assess the economic burden of chronic HCV infection from a national health insurance perspective and the impact of direct\u2010acting antivirals (DAAs) using nationwide real\u2010world data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with chronic HCV infection were identified from the French Health Insurance Claims Databases (SNDS) and matched for age and sex to the general population. Health resource utilization and reimbursements were summarized according to healthcare expenditure items from 2012 to 2021. The economic burden attributable to chronic HCV infection was evaluated over a 10\u2010year period. Finally, the impact of DAAs was estimated using economic data derived from the SNDS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 145\u2009187 patients with chronic HCV infection were identified. Among the patients eligible for DAA therapy, 81.5% had received DAA by the end of 2021. Over a 10\u2010year period, managing patients with chronic HCV infection resulted in an additional cost of \u20ac9.71 billion (95% confidence interval [CI]: \u20ac9.66\u2013\u20ac9.78 billion) or \u20ac9191 (95% CI: \u20ac9134\u2013\u20ac9252) per patient per year compared to the general population. After DAA therapy, patients with chronic HCV infection had a higher economic burden than the general population, with an additional cost of \u20ac5781 (95% CI: \u20ac5540\u2013\u20ac6028) per patient at the fifth\u2010year post\u2010DAA therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>A significant economic burden persists among patients with HCV infection after DAA treatment. The high proportion of patients not treated with DAA therapy supports reinforcing policies for universal access.<\/jats:p><\/jats:sec>","DOI":"10.1111\/liv.15872","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T12:05:38Z","timestamp":1708430738000},"page":"1233-1242","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Real\u2010world economic burden of hepatitis C and impact of direct\u2010acting antivirals in France: A nationwide claims data analysis"],"prefix":"10.1111","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3857-9604","authenticated-orcid":false,"given":"Laurent","family":"Lam","sequence":"first","affiliation":[{"name":"INSERM, Institut Pierre Louis d'\u00c9pid\u00e9miologie et de Sant\u00e9 Publique, IPLESP Sorbonne Universit\u00e9  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Carrieri","sequence":"additional","affiliation":[{"name":"INSERM, IRD, SESSTIM, Sciences Economiques &amp; Sociales de la Sant\u00e9 &amp; Traitement de l'Information M\u00e9dicale, ISSPAM Aix Marseille Univ  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Hejblum","sequence":"additional","affiliation":[{"name":"INSERM, Institut Pierre Louis d'\u00c9pid\u00e9miologie et de Sant\u00e9 Publique, IPLESP Sorbonne Universit\u00e9  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Bellet","sequence":"additional","affiliation":[{"name":"INSERM, Institut Pierre Louis d'\u00c9pid\u00e9miologie et de Sant\u00e9 Publique, IPLESP Sorbonne Universit\u00e9  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Bourli\u00e8re","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology H\u00f4pital Saint Joseph  Marseille France"},{"name":"INSERM, UMR 1252 IRD SESSTIM Aix Marseille Universit\u00e9  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Carrat","sequence":"additional","affiliation":[{"name":"INSERM, Institut Pierre Louis d'\u00c9pid\u00e9miologie et de Sant\u00e9 Publique, IPLESP Sorbonne Universit\u00e9  Paris France"},{"name":"Department of Public Health, Assistance Publique\u2010H\u00f4pitaux de Paris, H\u00f4pital Saint\u2010Antoine Sorbonne Universit\u00e9  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,2,20]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2008.01934.x"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32111-1"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100281"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(14)70365-1"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12311"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12546"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0194329"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14862"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0000000000001745"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13788"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.respe.2017.05.004"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2017.03.012"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26218"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-019-00861-x"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.5009\/gnl17034"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14382"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2015.08.006"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2012.11.004"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25842"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semradonc.2019.05.009"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa823"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.031"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5576"},{"key":"e_1_2_14_25_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-074001","article-title":"Mortality rates among patients successfully treated for hepatitis C in the era of interferon\u2010free antivirals: population based cohort study","volume":"382","author":"Hamill V","year":"2023","journal-title":"BMJ"},{"key":"e_1_2_14_26_1","first-page":"S131","article-title":"Assessing the burden of illness of chronic hepatitis C and impact of direct\u2010acting antiviral use on healthcare costs in Medicaid","volume":"25","author":"Roebuck MC","year":"2019","journal-title":"Am J Manag Care"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15550"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-020-05478-6"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-4493-2"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-022-03749-8"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14208"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.14820"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.15872","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T12:28:30Z","timestamp":1714048110000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.15872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,20]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1111\/liv.15872"],"URL":"https:\/\/doi.org\/10.1111\/liv.15872","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,20]]},"assertion":[{"value":"2023-10-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}